Leave your contact details and we'll be happy to respond
As the smallest hollow needle in the market (just 0.6mm long), MicronJetTM microneedle allows for a practically painless intradermal injection8,9
When it comes to microneedles, less is more
Our extensive clinical trials have shown improved immunogenicity and dose sparing over both intramuscular1-7,10 and subcutaneous8 delivery, as well as over intradermal delivery using the Mantoux technique3
Due to its unique design the MicronJetTM microneedle is one of the shallowest and most consistent forms of intradermal delivery4-9
VALIDATED BENEFITS
MicronJetTM has demonstrated a superior immune response with full dose2,3,5, 8,10 and equivalence or a trend for superiority with lower doses (4-40%)1-8,10
NUMEROUS TRIALS
In addition to global commercial sales, NanoPass’ MicronJetTM
Technology has been used to administer over 27,000 injections to approximately 5,700 patients in more than 55 completed and ongoing clinical trials
Intradermal delivery
Intradermal vaccine delivery has been repeatedly shown to allow significant dose sparing when compared to conventional administration methods**
Robust design
NanoPass’ MicronJetTM microneedles are based on MEMS (Micro electro mechanical Systems) technology and are made of pure silicon crystal
How to perform a MicronJet600 injection
The beauty of a MicronJet600 injection into the air
*See references
**Darin Zehrung et al. intradermal delivery for vaccine dose sparing: overview of current issues. Vaccine 31 (2013) 3392-3395
HOME | PRODUCT | TECHNOLOGY | CLINICAL | COMPANY PROFILE | TEAM & BOD | FAQ | CONTACT
Website revision 03
© Copyright 2020 All Rights Reserved by NANOPASS TECHNOLOGIES Ltd.
